Status:
COMPLETED
Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience
Lead Sponsor:
Tuen Mun Hospital
Conditions:
Rheumatoid Arthritis
Drug Use
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record ...
Detailed Description
This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record ...
Eligibility Criteria
Inclusion
- All RA patients in our biologics registry treated with the JAK inhibitors (N=411)
- All RA patients in our biologics registry treated with the TNF inhibitors (N=1392)
Exclusion
- \- RA patients in our biologics registry treated with other biologic/targeted DMARDs
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
1732 Patients enrolled
Trial Details
Trial ID
NCT05182203
Start Date
March 1 2022
End Date
October 1 2022
Last Update
February 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Tuen Mun Hospital
Hong Kong, China, 000